Jun, Jongsu
Gim, Jungsoo
Kim, Yongkang
Kim, Hyunsoo
Yu, Su Jong
Yeo, Injun
Park, Jiyoung
Yoo, Jeong-Ju
Cho, Young Youn
Lee, Dong Hyeon
Cho, Eun Ju
Lee, Jeong-Hoon
Kim, Yoon Jun
Lee, Seungyeoun
Yoon, Jung-Hwan
Kim, Youngsoo
Park, Taesung
Article History
First Online: 31 December 2018
Ethics approval and consent to participate
: To identify candidate serum hepatocellular carcinoma (HCC) biomarkers for prognosis and response to the tyrosine kinase inhibitor sorafenib, data from 115 HCC patients who had undergone continuous administration of sorafenib for more than 6 weeks, were collected from Seoul National University Hospital, as part of an ongoing study between May 2013 and August 2014. HCC was diagnosed by histological or radiological evaluation, with reference to the American Association for the Study of Liver Diseases (AASLD) [CitationRef removed] or the European Association for the Study of the Liver (EASL) [CitationRef removed] guidelines. All procedures/analyses were approved by the Seoul National University Hospital Institutional Review Board (IRB protocol No. 0506–150-005).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.